CAR T-Cell Therapy Has High Response Rate in Non-Hodgkin Lymphoma – Curetoday.com
Curetoday.com |
CAR T-Cell Therapy Has High Response Rate in Non-Hodgkin Lymphoma
Curetoday.com JCAR017, a CAR T-cell therapy, had a high objective response rate (80 percent), including a complete response rate of 60 percent for patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma, according to findings from TRANSCEND, … |
